Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma

After two decades of unchanged paradigms, the treatment strategies for advanced urothelial bladder cancer have been revolutionized by emerging programmed death ligand-1 (PD-L1)/programmed death-1 (PD1) inhibition therapy. Increased evidence is demonstrating the efficacy of PD-L1/PD1 inhibition thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Wei-Bo, Rao, Jian-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Medical Association 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6926111/
https://www.ncbi.nlm.nih.gov/pubmed/31891128
http://dx.doi.org/10.1016/j.cdtm.2019.08.003